External IRB Review What Does it Mean for Your Institution

Size: px
Start display at page:

Download "External IRB Review What Does it Mean for Your Institution"

Transcription

1 External IRB Review What Does it Mean for Your Institution Wesley G Byerly, Pharm.D. Associate Vice President for Research Integrity and Regulatory Affairs University of Connecticut and UCONN Health HCCA Research Compliance Conference June 5 8, 2016 Baltimore, MD What are IRBs Charged to Do? Notify investigators and the institution in writing of its decision to approve or disapprove the proposed research activity, or of modifications required to secure IRB approval of the research activity Conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once per year Have the authority to observe or have a third party observe the consent process and the research Have the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. Maintain adequate documentation of IRB activities 45 CFR 46 1

2 What are IRBs Charged to Do? Approve, require modifications in (to secure approval), or disapprove research activities Require that information given to subjects as part of informed consent is in accordance with regulation May require that additional information be given to the subjects when in the IRB's judgment the information would meaningfully add to the protection of the rights and welfare of subjects Require documentation of informed consent or may waive documentation 45 CFR 46 What are the Institutions Responsibilities? Designation of one or more IRBs Ensure designated IRBs have: A list of IRB members Written procedures Written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the department or agency head of Any unanticipated problems involving risks to subjects or others Any serious or continuing noncompliance with this policy or the requirements or determinations of the IRB Any suspension or termination of IRB approval Ensuring all other institutional and regulatory requirements are met 45 CFR 46 2

3 Process Submission IRB Review Require Modifications Approve Disapprove Return to Investigator Notify Investigator Notify Investigator Other Institutional or Regulatory Requirements Begin Study Research Study Models Single site Multi site Sites conducting the same protocol Multi site Multiple sites recruiting and involved in study interventions Coordinating center Statistical / data center Lab/ Reading / Bio specimen analysis 3

4 Why Rely on Another IRB? The federal system for protecting research subjects was designed decades ago, when most research studies took place at a single institution. These days, if a study is conducted at multiple sites, an ethics review by an institutional review board (IRB) may be repeated many times. This practice has been criticized for both wasting resources and leading to inappropriate delays in the conduct of research. Jerry Menikoff, Director OHRP Variability in Multi IRB Review Academic Medicine, Vol. 87, No. 12 / December

5 Variability in Multi IRB Review Design: Descriptive analysis of survey information and informed consent forms from 16 IRBs from the institutions participating in a multicenter trial comparing lower vs. traditional tidal volume ventilation in patients with acute lung injury. Results: Surveys and IRB approved consent forms were obtained from all of the contacted IRBs (n = 16). Variability was observed among several of the research practices; one IRB waived the requirement for informed consent, five IRBs permitted telephone consent, and three IRBs allowed prisoners to be enrolled. Three consent forms contained all of the basic elements of informed consent outlined in the federal regulations, and 13 forms had varying numbers of these elements absent (six forms without one element, four without two, one without three, and two without four). Reading levels of the consent forms ranged from grades 8.2 to 13.4 (mean 6 SD was grade level) Crit Care Med 2001;29: Variability in Multi IRB Review Design: 82 investigators from 44 US medical centers were surveyed regarding their local IRB (e.g., frequency of meetings, membership), IRB queries and concerns related submission of a multicenter, randomized, double blind, placebo controlled trial of outpatient therapy for acute asthma. Results: Both surveys had 100% response rate. Investigators submitted applications a median of 58 days (interquartile range [IQR], 40 83) after receipt of the protocol, and IRB approval took an additional 38 days (IQR, 26 62). Although eight applications were approved with little or no changes, IRBs requested an average of 3.5 changes per site. Changes involved study logistics and supervision for 45%, the research process for 43%, and the consent form for 91%. Despite these numerous requests, all eventually approved the basic protocol, including inclusion criteria, intervention, and data collection. Academic Emerg Med 2001; 8:

6 Variability in Multi IRB Review Design: a systematic review of the empirical literature evaluating IRBs included an analysis of 16 published studies located that evaluated variation in the processes and/or outcomes of review by different IRBs for multicenter studies. Results: The studies demonstrated variation in: Type of review required Time required to review the proposed research Designation of risk level Acceptable methods for recruitment of subjects Number and type of IRB concerns expressed or changes required J Empir Res Hum Res Ethics March ; 6(1): 3 19 Challenges and Barriers to Non Local IRB Review Review quality Local context Regulatory and legal liability Control and accountability Logistics Loss of income BMC Medical Ethics 2011, 12:13 Using Central IRBs for Multicenter Clinical Trials in the United States PLoS ONE 8(1): e doi: /journal.pone

7 Common Rule and FDA regulations provide for External IRB and other cooperative IRB review arrangements OHRP Cooperative research projects are those projects which involve more than one institution. [An] institution participating in a cooperative project may enter into a joint review arrangement, rely upon the review of another qualified IRB, or make similar arrangements for avoiding duplication of effort. FDA institutions involved in multi institutional studies may use joint review, reliance upon the review of another qualified IRB, or similar arrangements aimed at avoidance of duplication of effort. 21 CFR CFR To Rely on a Non Institutional IRB Must document arrangement in a written agreement that outlines [the] relationship and includes a commitment that the IRB will adhere to the requirements of the institution s FWA (OHRP s Terms of FWA #6) IRB Authorization Agreement (IAA), also called Reliance Agreement, negotiated and executed Policies and procedures to delineate responsibilities implemented External IRB ensures process and ability to addresses local issues OHRP 7

8 NPRM Why Now? Any institution located in the United States that is engaged in cooperative research must rely upon approval by a single IRB for that portion of the research that is conducted in the United States. The reviewing IRB will be selected by the Federal department or agency supporting or conducting the research or, if there is no funding agency, by the lead institution conducting the research. Federal Register /Vol. 80, No. 173 /Tuesday, September 8, 2015 / Proposed Rules Why Now? Request for Comments on the Draft NIH Policy on the Use of a Single Institutional Review Board for Multi Site Research Release Date: December 3, 2014 Response Date: January 29, 2015 Purpose: The National Institutes of Health (NIH) is seeking public comments on a draft policy to promote the use of a single Institutional Review Board of record for domestic sites of multi site studies funded by the NIH. files/not OD html#sthash.pb6R5AAT.dpuf 8

9 Why Now NIDDK: Type 1 Diabetes TrialNet Clinical Centers (U01) Posted June 18, files/rfa DK html Central Institutional Review Board (IRB) NIDDK will give preference to Clinical Centers agreeing to use a central IRB of record to accelerate IRB approval in multi center trials. To that effect, the network will use a federated" IRB model. This model gives participating institutions the option to choose one of three tiers of IRB review: Tier 1 indicates reliance on a central IRB as IRB of record; Tier 2 indicates designation of a central IRB as IRB of record in addition to involvement of a local IRB; Tier 3 indicates reliance on a local IRB. Why Now? 21st Century Cures Act Independent versus Institutional IRB Review Calls for rule changes that reduce delays, updates language to accommodate multi site studies, and acknowledge any local concerns Requires that all research allow the possibility for central review, whether that is by independent IRB, joint review, or another institution s IRB Requires that new guidelines address concerns over local liability for decisions made elsewhere. Calls for continued local review by incorporating community values through the use of local institutional review boards. Could complicate IRB review across multiple sites, possibly by requiring a shared review of any research Central IRB Review for Devices Changes device regulations to match corresponding drug research guidelines and allow central IRB review of device studies 9

10 Non Institutional IRB review models Facilitated Review A shared responsibility between central and local IRB The central IRB makes initial decisions, and then a local IRB rereviews the decisions and possibly amends them Example: National Cancer Institute s CIRB used a facilitated model until Reliance Model IRBs share SOPs, informed consent documents and other information that allows IRBs to pool resources, compare best practices, facilitate work on multi site studies and sometimes accept each other s decisions Example: IRBChoice Quorum IRB 2016 National Conference on Alternative IRB Models, Nov 19 21, 2006 Non Institutional IRB review models Lead IRB or IRB of Record A model common to NIH funded studies. In a multi site study, the sponsor of a multi site study establishes one institution s IRB to oversee the study. The other locations can accept that jurisdiction, or opt to review the research themselves.. Example: NeuroNEXT Consortium/Regional A group of research sites, universities or hospitals share form a new entity to manage, audit and monitor research, and provide IRB oversight Example: BRANY Quorum IRB 2016 National Conference on Alternative IRB Models, Nov 19 21,

11 Non Institutional IRB review models Independent IRBs Free standing review committees which have no direct or permanent affiliation to a research organization conducts review on behalf of one or more research sites, which accept the independent review (no local review by each site). Independent IRBs can have review authority over one, some, or all of the sites in one protocol, over some portion of an institution s research such as all clinical trials, or over a single protocol. Examples: Quorum, Western IRB (WIRB), Schulman, New England and others Quorum IRB 2016 National Conference on Alternative IRB Models, Nov 19 21, 2006 Decoupling Responsibilities Organizational Considerations Who decides Process for institutional Review Who can execute an IAA Scope of Review Single Protocol Multiple Protocols By type of research Specific group of institutions By funding All Protocols 11

12 Decoupling Responsibilities Organizational Considerations How does the institution determine the IRB it will be relying on meets its standards for the protection of human subjects Oversight of reviewing IRB Study monitoring /audit /oversight Agency specific or other review requirements State / local laws Check / Uncheck the box Decoupling Responsibilities Organizational Considerations Metrics How are non local reviewed studies counted Insurance Advertising approval Use of name FOIA Sponsored Programs / Financial Systems Secondary reliance (you rely but others rely on you or VA) 12

13 Decoupling Responsibilities IRB related considerations Scientific review Unanticipated Problems and Noncompliance determination and reporting Who investigates Who reviews Who determines corrective actions Who drafts correspondence Who reports Decoupling Responsibilities IRB related considerations Conflict of Interest Investigator, Institutional, IRB member Grant congruence Suspension and Terminations Lapses of approval Training and qualification of study team Adequacy of resources 13

14 Decoupling Responsibilities Clinical Trials Considerations CTMS Clinical trials coverage analysis Subject injury terms Clinicaltrials.gov Contract congruence Decoupling Responsibilities Ancillary Organizational Considerations HIPAA Covered, hybrid or uncovered entities Waiver to recruit/screen Authorization Review Compounded or Stand Alone Authorizations FERPA Radiation Safety Biosafety Pharmacy / Device Sponsored Programs / Financial Systems Departmental or Unit review 14

15 Institutional Responsibility Acceptability Determine if the proposed research study is acceptable or appropriate for its investigators to conduct Is the disease, condition, or issue to be studied acceptable to the organization? Is the organization supportive of the proposed methods or expected outcomes of the study? Are there procedures proposed in the research that differ from the standard of practice in the institution? Are the investigator and staff qualified to conduct the study? Using Central IRBs for Multicenter Clinical Trials in the United States. PLoS ONE 8(1):e doi: /journal.pone Institutional Responsibility Acceptability Does the organization and/or investigator have the resources available to carry out the study? Does the proposed research violate any organizational policies or local laws/regulations? What will community reactions be to the research? Are there any funding issues associated with the research? Do the investigators, staff or the institution have a financial conflict of interest related to the research? Using Central IRBs for Multicenter Clinical Trials in the United States. PLoS ONE 8(1):e doi: /journal.pone

16 Institutional Responsibility Accountability Provide oversight of the research study Conduct institutional reviews such as conflict of interest, radiation safety, biosafety reviews, and facility Ensure ICF, recruitment materials and other documents include local information and adaptations Establish a process to receive, review, manage and report to reviewing IRB local unanticipated problems, adverse events, noncompliance, complaints Conduct study monitoring or audits Maintain accountability of investigators and study staff Using Central IRBs for Multicenter Clinical Trials in the United States. PLoS ONE 8(1):e doi: /journal.pone Reviewing IRB Responsibility Review of the ethics of the study Review of the study design Confirm the competency of the investigator Review proposed research according to applicable regulatory criteria Ensure the quality of ICFs, recruitment materials and other documents, and inclusion/adaption of local information Review, manage and report unanticipated problems, adverse events, noncompliance, and complaints submitted by sites Determine that institutional oversight and accountability is appropriate and acceptable Using Central IRBs for Multicenter Clinical Trials in the United States. PLoS ONE 8(1):e doi: /journal.pone

17 Questions? 17

Collaboration and Efficiency in IRB review of Multi-Site Research

Collaboration and Efficiency in IRB review of Multi-Site Research Collaboration and Efficiency in IRB review of Multi-Site Research Human Subject Research Community Conference University of Miami Student Activities Center (SAC) September 11, 2014 Cynthia Hahn VP, Clinical

More information

Human Subjects Protection Program Plan

Human Subjects Protection Program Plan December 1, 2016 HRP-101 12/1/16 2 of 12 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research... 3 Human Research:... 4 Human Subject as Defined

More information

Human Research Protection Program. Plan

Human Research Protection Program. Plan Human Research Protection Program Plan Revised September 6, 2017 HRP-101 9/6/17 2 of 13 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...

More information

ANPRM Single IRB Review mandated for multi-site domestic research. P. Pearl O Rourke, M.D. Partners Health Care

ANPRM Single IRB Review mandated for multi-site domestic research. P. Pearl O Rourke, M.D. Partners Health Care ANPRM Single IRB Review mandated for multi-site domestic research P. Pearl O Rourke, M.D. Partners Health Care Life would be grand! If I only had a single IRB! Points to be made Proposed benefits of single/central

More information

HUMAN RESEARCH PROTECTION PROGRAM PLAN

HUMAN RESEARCH PROTECTION PROGRAM PLAN HUMAN RESEARCH PROTECTION PROGRAM PLAN HRP 101 June 2017 706-542-3199 irb@uga.edu https://research.uga.edu/hso/ Table of Contents Scope... 2 Purpose... 2 Definitions... 2 Agent... 2 Clinical Trial... 2

More information

Advocate Health Care Network. Human Research Protection Program. Plan

Advocate Health Care Network. Human Research Protection Program. Plan Advocate Health Care Network Human Research Protection Program Plan Revised October 19, 2014 Page 1 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Clinical Trial... 3 Engaged in Human Research...

More information

Human Research Protection Program Plan

Human Research Protection Program Plan Revised January 19, 2018 Table of Contents Human Research Protection Program Plan HRP-101 1/19/2018 2 of 13 Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...

More information

Human Research Protection Program Policy

Human Research Protection Program Policy Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may

More information

Developing a Written Reliance Agreement with a Central IRB

Developing a Written Reliance Agreement with a Central IRB Developing a Written Reliance Agreement with a Central IRB 02/02/16 description One of the first steps for an institution that will defer IRB jurisdiction to another is to execute a reliance agreement.

More information

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients

More information

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance

What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing

More information

Human Research Protection Program. Plan

Human Research Protection Program. Plan Human Research Protection Program Plan Dated: September 4, 2014 HRP-101 9/4/2014 2 of 14 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...

More information

Human Research Protection Program Compliance Plan

Human Research Protection Program Compliance Plan Human Research Protection Program Compliance Plan May 1, 2016 Human Research Protections Program e 1313 21 st Ave. South, Room 504, Nashville, Tennessee 37232 4315 e phone 615-322-2918 e fax 615-343-2648

More information

Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD

Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD Interim Analysis of Randomized Clinical Trials David L DeMets, PhD Need for Data Monitoring Phase I Trials (dose) Monitoring usually at local level Phase II Trials (activity) Most monitoring at local level

More information

GW Policy on Human Research Protection Program

GW Policy on Human Research Protection Program GW Policy on Human Research Protection Program 1. PURPOSE 1.1. This policy establishes the [Organization] s Human Research Protection Program (HRPP) and its commitment to protect the rights and welfare

More information

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014

Annual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014 Annual Research Administrators Symposium IRB Compliance Thursday, July 31, 2014 Why IRB Compliance Is Required for Grant Submissions Topics to Cover Today What is an IRB? Why IRB review is required? Regulatory

More information

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19 POLICY #: MULTI-100 Page: 1 of 4 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center research must comply

More information

University of Utah Annual IRB Member Training Ann Johnson, PhD Associate Director Institutional Review Board

University of Utah Annual IRB Member Training Ann Johnson, PhD Associate Director Institutional Review Board University of Utah Annual IRB Member Training 2016 Ann Johnson, PhD Associate Director Institutional Review Board Overview of NIH policy on the use of a Single IRB for multi site research (and other federal

More information

3.0 HSC Relation to Other KUMC Committees

3.0 HSC Relation to Other KUMC Committees 3.0 HSC Relation to Other KUMC Committees It is the policy of the HSC to work in conjunction with other KUMC Committees to provide protections to research subjects. The HSC coordinates reviews with other

More information

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING DATA AND SAFETY MONITORING September 2009 Joey Casanova, BBA, CIP Human Subject Research Office SECTION 1 BACKGROUND PURPOSE Data and safety monitoring is the process for reviewing accumulated outcome

More information

Trends in Oversight of Human Research Protections?

Trends in Oversight of Human Research Protections? Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for

More information

IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol

IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol Use this checklist to assemble your request for your institution s IBC to review a specific protocol. If WIRB does not already administer

More information

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ

Good Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of

More information

1.0 INTRODUCTION AND OVERVIEW

1.0 INTRODUCTION AND OVERVIEW Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...

More information

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn

More information

Rules of Human Experimentation

Rules of Human Experimentation Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office

More information

Standard Operating Procedures Guidelines for Good Clinical Practice

Standard Operating Procedures Guidelines for Good Clinical Practice SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA

More information

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School

More information

ELEMENTS OF A DATA MONITORING PLAN

ELEMENTS OF A DATA MONITORING PLAN ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and

More information

GCP Convergence Improves Transportability of Medical Device Clinical Data

GCP Convergence Improves Transportability of Medical Device Clinical Data GCP Convergence Improves Transportability of Medical Device Clinical Data By Harmonization-by-Doing Working Group 4 The safety, performance and effectiveness of medical devices are often evaluated by well-controlled

More information

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the

More information

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National

More information

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of

More information

Volunteering for Clinical Trials

Volunteering for Clinical Trials Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials

What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)

More information

Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5

Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5 THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 001.2 Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5 Written by: Laura W. Knight,

More information

Northwestern University HSPP Policy Manual Page 2 of 116

Northwestern University HSPP Policy Manual Page 2 of 116 Northwestern University HSPP Policy Manual Page 2 of 116 POLICY FOR HUMAN SUBJECTS RESEARCH AT NORTHWESTERN UNIVERSITY 8 I. PREAMBLE: 8 II. OVERVIEW OF THE IRB, OPRS, AND THE HUMAN SUBJECT PROTECTION PROGRAM

More information

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School

More information

2013 Metrics on Human Research Protection Program Performance

2013 Metrics on Human Research Protection Program Performance 2013 Metrics on Human Research Protection Program Performance Updated August 1, 2014 About the Metrics Improving the quality of human research protection programs (HRPP) is a top priority of AAHRPP. Effective

More information

VCU Faculty Held IND and IDE Procedure Handbook

VCU Faculty Held IND and IDE Procedure Handbook VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted

More information

Outline of Discussion

Outline of Discussion This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are

More information

PROTOCOL-SPECIFIC DOCUMENT

PROTOCOL-SPECIFIC DOCUMENT PROTOCOL-SPECIFIC DOCUMENT To Collect Institutional Requirements from Relying Institutions Institutional, Local, and State Requirements Working Group of the SMART IRB Harmonization Steering Committee July

More information

Protection of Research Participants: The IRB Process and the Winds of Change

Protection of Research Participants: The IRB Process and the Winds of Change Protection of Research Participants: The IRB Process and the Winds of Change Ethics in Patient-Oriented Research October 12, 2011 Sharon Friend Director, OHRPP Overview Charge and Function of the IRB Quick

More information

EVENT TYPE TIMING REQUIRED FORM

EVENT TYPE TIMING REQUIRED FORM Reportable Events EVENT TYPE TIMING REQUIRED FORM Unanticipated Problem or Adverse Event 10 days Event Reporting Form Death (related) 10 days Event Reporting Form Death (not related) Renewal Summary with

More information

US Special Operations Command Human Research Protection Office

US Special Operations Command Human Research Protection Office S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States

More information

June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB

June 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits

More information

What is an IRB (Institutional Review Board)?

What is an IRB (Institutional Review Board)? What is an IRB (Institutional Review Board)? The Belmont Report The Belmont Report on the Ethical Principles and Guidelines for the Protection of Human Subjects of Research was prepared by the National

More information

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010 IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized

More information

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit Off-Label Use Versus Clinical Trial Use of Devices: FDA Regulatory Issues Neil F. O Flaherty Principal Olsson Frank Weeda Terman Bode Matz PC Off-Label Use Uses that do not appear in a device s FDA-approved

More information

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:

More information

Advancing the Use of Central IRBs for Multicenter Clinical Trials

Advancing the Use of Central IRBs for Multicenter Clinical Trials Advancing the Use of Central IRBs for Multicenter Clinical Trials Cynthia Hahn, Chief Operating Officer, The Feinstein Institute for Medical Research July 10, 2015 CTTI Mission To identify and promote

More information

INSTITUTION V. IRB RESPONSIBILITIES

INSTITUTION V. IRB RESPONSIBILITIES INSTITUTION V. A guide for Reviewing s and Relying Institutions using the SMART Agreement or other reliance agreements Institution v. Responsibilities Working Group of the SMART Harmonization Steering

More information

RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH

RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH 1. Overview RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH The ethical and regulatory requirements of The Ohio State University Human Research Protection Program (HRPP) apply to all research

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

TITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1.

TITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1. POLICY #: MULTI-100 Page: 11 of 54 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center Trialsresearch

More information

Clinical Trials Management for Molecular Diagnostics. April 2016

Clinical Trials Management for Molecular Diagnostics. April 2016 Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective

More information

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit? Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination

More information

Cynthia Gates JD RN CIP

Cynthia Gates JD RN CIP Regulatory Update HCCA Research Compliance Conference June 3-6, 2012 Cynthia Gates JD RN CIP April 2012 FDA OHRP HIPAA 1 Final Guidance Continuing Review Safety Reporting Monitoring New Consent form Element

More information

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction

More information

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics 11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure

More information

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1 APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1 The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed

More information

EFFECTIVELY IMPLEMENTING THE NIH SINGLE IRB POLICY AND REVISED COMMON RULE

EFFECTIVELY IMPLEMENTING THE NIH SINGLE IRB POLICY AND REVISED COMMON RULE EFFECTIVELY IMPLEMENTING THE NIH SINGLE IRB POLICY AND REVISED COMMON RULE 2018 SRA MIDWEST/SOUTHERN SECTION MEETING ST. LOUIS, MO Wednesday, April 18, 2018 10:30 AM - 11:45 AM 2018 HURON CONSULTING GROUP

More information

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Human Research Audit Program Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance Monday, September 11, 2017 Objectives 1. Understand the purpose of the audit program 2. Identify

More information

Compliance and Quality Monitoring: What, Why, When, and How

Compliance and Quality Monitoring: What, Why, When, and How Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University

More information

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting

Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting February 16, 2016 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND

More information

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in

More information

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

EIGHT BASIC ELEMENTS OF INFORMED CONSENT 1/6 This guidance addresses: o Eight Basic elements of informed consent o Additional elements of informed consent o Other information required by the IRB EIGHT BASIC ELEMENTS OF INFORMED CONSENT Required

More information

Effective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP

Effective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP Policy Title: Education and Quality Improvement Program EQuIP Effective Date: October 8, 2015 Policy Number: Review Date: October 8, 2015 Section: Revised Date: Administrative Responsibility: Oversight

More information

IEC Best Practices: Standard Operating Procedures

IEC Best Practices: Standard Operating Procedures IEC Best Practices: Standard Operating Procedures David Borasky, MPH, CIP Office of Research Protections RTI International Research Triangle Park, North Carolina, USA Introduction IECs are complex units

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

NIH Policy Priorities for Clinical Research

NIH Policy Priorities for Clinical Research NIH Policy Priorities for Clinical Research Kathy Hudson, Ph.D. Deputy Director for Science, Outreach, and Policy, NIH Federal Demonstration Partnership January 12, 2015 Topics Clinical Trial Results Reporting

More information

COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS

COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS COOPERATIVE RESEARCH AND EXTERNAL INVESTIGATORS Table of Contents I. OHRP Guidance on Engagement of Institutions in Human Subjects Research... 2 II. External Investigators: The institution in question

More information

Long-Term Follow-Up in Gene Transfer Clinical Research

Long-Term Follow-Up in Gene Transfer Clinical Research Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection

More information

Institutional Biosafety Committee. Policies and Procedures

Institutional Biosafety Committee. Policies and Procedures Institutional Biosafety Committee Policies and Procedures September 2011 CONTENTS 1. INTRODUCTION 1.1 UNLV Institutional Biosafety Committee Roles and Responsibilities 1.2 The Foundation for IBC Review:

More information

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical

More information

Investigator Manual Revised August 19, 2013

Investigator Manual Revised August 19, 2013 Investigator Manual Revised August 19, 2013 Investigator Manual Page 2 of 31 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection

More information

Human Subjects Research Policy Update. Naomi Coll Director of Research Policy and Compliance

Human Subjects Research Policy Update. Naomi Coll Director of Research Policy and Compliance Human Subjects Research Policy Update Naomi Coll Director of Research Policy and Compliance Major Policy Updates 1. Activities that meet the HHS or FDA definition of human subjects research are subject

More information

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You

More information

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time

More information

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed

More information

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage

More information

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational

More information

Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in

Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in order to reap the benefits. 26 Practical Dermatology

More information

International Research Basic Topics to Consider. International Subcommittee Regulatory Foundations, Ethics and Law Program

International Research Basic Topics to Consider. International Subcommittee Regulatory Foundations, Ethics and Law Program International Research Basic Topics to Consider International Subcommittee Regulatory Foundations, Ethics and Law Program Presentation Outline Study Planning, Implementation, and Monitoring Considerations

More information

Dr. David D. Lee, Provost and VP for Academic Affairs

Dr. David D. Lee, Provost and VP for Academic Affairs POLICY & PROCEDURE DOCUMENT NUMBER: 2.7000 SECTION: TITLE: Research Institutional Biosafety Committee Policy DATE: November 6, 2017 Authorized by: Dr. David D. Lee, Provost and VP for Academic Affairs

More information

Embryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures

Embryonic Stem Cell Research Oversight (ESCRO) Committee. Policies and Procedures University of California, Los Angeles Embryonic Stem Cell Research Oversight (ESCRO) Committee TABLE OF CONTENTS Section Page 1.0 Purpose... 2 2.0 Authority... 2 3.0 Function... 2 4.0 Review... 2 4.1 Review

More information

Investigator s Handbook

Investigator s Handbook Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.

More information

MCW Office of Research Standard Operating Procedure

MCW Office of Research Standard Operating Procedure MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DEVICES Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW Faculty and Staff involved

More information

13.0 Quality Improvement in the HRPP Program

13.0 Quality Improvement in the HRPP Program 13.0 Quality Improvement in the HRPP Program 13.1 Definitions Quality Improvement: A process initiated to develop/enhance a practice or procedure and to institutionalize the practice or procedure. Audit:

More information

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations. POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that

More information

Investigator Manual. Human Subjects Protection Program

Investigator Manual. Human Subjects Protection Program Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the

More information

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities

More information

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act

More information

Definition of Human Subject (94% oppose, 3% support, 3% support with qualifiers)

Definition of Human Subject (94% oppose, 3% support, 3% support with qualifiers) Research Universities and Institutions; Medical Centers and Schools of Medicine; Academic Institutional Review Boards and University and Medical Center Staff Preliminary Findings from a Review of Responses

More information

Implementing Good Clinical Practice at an Academic Research Institution

Implementing Good Clinical Practice at an Academic Research Institution Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of

More information

FDA Perspective on Data Quality Rachel E. Sherman, MD, MPH Associate Director for Medical Policy Center for Drug Evaluation and Research

FDA Perspective on Data Quality Rachel E. Sherman, MD, MPH Associate Director for Medical Policy Center for Drug Evaluation and Research FDA Perspective on Data Quality Rachel E. Sherman, MD, MPH Associate Director for Medical Policy Center for Drug Evaluation and Research IOM Workshop - Implementing a National Cancer Clinical Trials System

More information

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312

More information

Human Research Protections Program Policies and Standard Operating Procedures

Human Research Protections Program Policies and Standard Operating Procedures Human Research Protections Program Policies and Standard Operating Procedures Version Date: April 2018 Presbyterian Healthcare Services Human Research Protections Office and Institutional Review Board

More information

Human Research Protection Program. Investigator Manual

Human Research Protection Program. Investigator Manual Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection

More information